Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison
Psycho-Oncology2014Vol. 24(4), pp. 472–477
Citations Over TimeTop 10% of 2014 papers
Morgan Lee, Heather Jim, Mayer Fishman, Babu Zachariah, Randy V. Heysek, Matthew C. Biagioli, Paul B. Jacobsen
Abstract
Findings support the hypothesis that ADT administration yields increases in depression and suggest that the mechanism behind ADT's association with depression should be explored and that prostate cancer patients treated with ADT should receive particular focus in depression screening and intervention.
Related Papers
- → Influence of radical prostatectomy on miRNA dynamics in urine extracellular vesicles(2024)3 cited
- → Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer(2011)9 cited
- → Androgen deprivation therapy for prostate cancer(2017)4 cited
- → Uncovering the Metabolic Complications of Androgen Deprivation Therapy in Patients with Prostate Cancer—Where Do We Take it Next?(2015)2 cited
- Complications of androgen deprivation therapy in prostate cancer / a review(2017)